- Approval Id
- 8188173276a3c328
- Drug Approval Emc Name
- PROCYSBI 75 mg gastro-resistant hard capsules
- Drug Name
- PROCYSBI 75 mg gastro-resistant hard capsules
- Company Name
- Chiesi Limited
- Company Address
- Chiesi Limited, 333 Styal Road, Manchester, M22 5LG
- Company Website
- http://www.chiesi.uk.com
- Company Telephone
- +44 (0) 161 488 5555
- Company Medical Info Direct Line
- +44 (0)1748 827 271
- Company Medical Info Email
- medinfo.uk@chiesi.com
- Atc Code
- A16AA04
- Legal Category
- Prescription only medicine
- Authorisation Holder
- Chiesi Limited
333 Styal Road
Manchester
M22 5LG
United Kingdom
- Authorisation Number
- \*\*PROCYSBI 25 mg hard capsule\*\*
PLGB 08829/0190
\*\*PROCYSBI 75 mg hard capsule\*\*
PLGB 08829/0191
- Authorisation Date
- 01/01/2021
- Instruction Authorisation Holder
- Chiesi Limited
333 Styal Road
Manchester
M22 5LG
United Kingdom
- Instruction Authorisation Number
- \*\*PROCYSBI 25 mg hard capsule\*\*
PLGB 08829/0190
\*\*PROCYSBI 75 mg hard capsule\*\*
PLGB 08829/0191
- Instruction Authorisation Date
- 01/01/2021
- Instruction Composition
- \*\*PROCYSBI 25 mg gastro-resistant hard capsule\*\*
Each gastro-resistant hard capsule contains 25 mg of cysteamine (as mercaptamine bitartrate).
\*\*PROCYSBI 75 mg gastro-resistant hard capsule\*\*
Each gastro-resistant hard capsule contains 75 mg of cysteamine (as mercaptamine bitartrate).
For the full list of excipients, see section 6.1.
- Instruction Dosage Form
- Gastro-resistant hard capsule.
\*\*PROCYSBI 25 mg\*\* \*\*gastro-resistant hard capsule\*\*
Light blue size 3 (15.9 x 5.8 mm) hard capsules imprinted “25 mg” in white ink and a light blue cap imprinted with “PRO” in white ink.
\*\*PROCYSBI 75 mg gastro-resistant hard capsule\*\*
Light blue size 0 (21.7 x 7.6 mm) hard capsules imprinted “75 mg” in white ink and a dark blue cap imprinted with “PRO” in white ink.
- Instruction Clinical Particulars
- 4.1 Therapeutic indications
PROCYSBI is indicated for the treatment of proven nephropathic cystinosis. Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.4.2 Posology and method of administration
PROCYSBI treatment should be initiated under the supervision of a physician experienced in the treatment of cystinosis.
Cysteamine therapy must be initiated promptly once the diagnosis is confirmed (i.e., increased WBC cystine) to achieve maximum benefit.
\*\*Posology\*\*
White blood cell (WBC) cystine concentration may for instance be measured by a number of different techniques such as specific WBC subsets (e.g., granulocyte assay) or the mixed leukocyte assay with each assay having different target values. Healthcare professionals should refer to the assay-specific therapeutic targets provided by individual testing laboratories when making decisions regarding diagnosis and PROCYSBI dosing for cystinosis patients. For example the therapeutic goal is to maintain a WBC cystine level < 1 nmol hemicystine/mg protein (when measured using the mixed leukocyte assay), 30 min after dosing For patients adherent to a stable dose of PROCYSBI, and who do not have easy access to an adequate facility for measuring their WBC cystine, the goal of therapy should be to maintain plasma cysteamine concentration > 0.1 mg/L, 30 min after dosing.
Measurement timing: PROCYSBI should be administered every 12 hours. The determination of WBC cystine and/or plasma cysteamine must be obtained 12.5 hours after the evening dose the day before, and therefore 30 minutes after the following morning dose is given.
\*\*\*Transferring patients from immediate-release cysteamine bitartrate hard capsules\*\*\*
Patients with cystinosis taking immediate-release cysteamine bitartrate may be transferred to a total daily dose of PROCYSBI equal to their previous total daily dose of immediate-release cysteamine bitartrate. Total daily dose should be divided by two and administered every 12 hours. The maximum recommended dose of cysteamine is 1.95 g/m2/day. The use of doses higher than 1.95 g/m2/day is not recommended (see section 4.4).
Patients being transferred from immediate-release cysteamine bitartrate to PROCYSBI should have their WBC cystine levels measured in 2 weeks, and thereafter every 3 months to assess optimal dose as described above.
\*\*\*Newly diagnosed adult patients\*\*\*
Newly diagnosed adult patients should be started on 1/6 to 1/4 of the targeted maintenance dose of PROCYSBI. The targeted maintenance dose is 1.3 g/m2/day, in two divided doses, given every 12 hours (see below table 1). The dose should be raised if there is adequate tolerance and the WBC cystine level remains > 1 nmol hemicystine/mg protein (when measured using the mixed leukocyte assay). The maximum recommended dose of cysteamine is 1.95 g/m2/day. The use of doses higher than 1.95 g/m2/day is not recommended (see section 4.4).
The target values provided in the SmPC are obtained from using the mixed leucocyte assay. It should be noted that therapeutic targets for cystine depletion are assay-specific and different assays have specific treatment targets. Therefore, healthcare professionals should refer to the assay-specific therapeutic targets provided by individual testing laboratories.
\*\*\*Newly diagnosed paediatric population\*\*\*
The targeted maintenance dose of 1.3 g/m2/day can be approximated according to the following table, which takes surface area as well as weight into consideration.
\*Table 1: Recommended dose\*
| | |
| --- | --- |
| \*\*Weight in kilograms\*\* | \*\*Recommended dose in mg\*\* \*\*Every 12 hours\\*\*\* |
| 0–5 | 200 |
| 5–10 | 300 |
| 11–15 | 400 |
| 16–20 | 500 |
| 21–25 | 600 |
| 26–30 | 700 |
| 31–40 | 800 |
| 41–50 | 900 |
| >50 | 1 000 |
\\*Higher dose may be required to achieve target WBC cystine concentration.
The use of doses higher than 1.95 g/m2/day is not recommended.
\*\*\*Missed doses\*\*\*
If a dose is missed, it should be taken as soon as possible. If it is within four hours of the next dose, the missed dose should be skipped going back to the regular dosing schedule. The dose should not be doubled.
\*\*\*Special populations\*\*\*
\*Patients with poor tolerability\*
Patients with poorer tolerability still receive significant benefit if white blood cell cystine levels are below 2 nmol hemicystine/mg protein (when measured using the mixed leukocyte assay). The cysteamine dose can be increased to a maximum of 1.95 g/m2/day to achieve this level. The dose of 1.95 g/m2/day of immediate-release cysteamine bitartrate has been associated with an increased rate of withdrawal from treatment due to intolerance and an increased incidence of adverse events. If cysteamine is initially poorly tolerated due to gastrointestinal (GI) tract symptoms or transient skin rashes, therapy should be temporarily stopped, then re-instituted at a lower dose and gradually increased to the appropriate dose (see section 4.4).
\*Patients on dialysis or post-transplantation\*
Experience has occasionally shown that some forms of cysteamine are less well tolerated (i.e. leading to more adverse events) when patients are on dialysis. A closer monitoring of the WBC cystine levels is recommended in these patients.
\*Patients with renal impairment\*
Dose adjustment is not normally required; however, WBC cystine levels should be monitored.
\*Patients with hepatic impairment\*
Dose adjustment is not normally required; however, WBC cystine levels should be monitored.
\*\*Method of administration\*\*
Oral use.
This medicinal product can be administered by swallowing the intact capsules as well as sprinkling the capsule contents (enteric coated beads) on food or delivery through a gastric feeding tube.
Do not crush or chew capsules or capsule contents.
\*\*\*Administration with food\*\*\*
Cysteamine bitartrate can be administered with an acidic fruit juice or water.
Cysteamine bitartrate should not be administered with food rich in fat or proteins, or with frozen food like ice-cream. Patients should try to consistently avoid meals and dairy products for at least 1 hour before and 1 hour after PROCYSBI dosing. If fasting during this period is not possible, it is acceptable to eat only a small amount (~ 100 grams) of food (preferentially carbohydrates) during the hour before and after PROCYSBI administration. It is important to dose PROCYSBI in relation to food intake in a consistent and reproducible way over time (see section 5.2).
In paediatric patients who are at risk of aspiration, aged approximately 6 years and under, the hard capsules should be opened and the content sprinkled on food or liquid listed in section 6.6.
For instructions about the medicinal product before administration, see section 6.6.4.3 Contraindications
• Hypersensitivity to the active substance, any form of cysteamine (mercaptamine), or to any of the excipients listed in section 6.1.
• Hypersensitivity to penicillamine.
• Breast-feeding.4.4 Special warnings and precautions for use
The use of doses higher than 1.95 g/m2/day is not recommended (see section 4.2).
Oral cysteamine has not been shown to prevent eye deposition of cystine crystals. Therefore, where cysteamine ophthalmic solution is used for that purpose, its usage should continue.
If a pregnancy is diagnosed or planned, the treatment should be carefully reconsidered and the patient must be advised of the possible teratogenic risk of cysteamine (see section 4.6).
Intact capsules of PROCYSBI should not be administered to children under the age of approximately 6 years due to risk of aspiration (see section 4.2).
\*\*Dermatological\*\*
There have been reports of serious skin lesions in patients treated with high doses of immediate-release cysteamine bitartrate or other cysteamine salts that have responded to cysteamine dose reduction. Physicians should routinely monitor the skin and bones of patients receiving cysteamine.
If skin or bone abnormalities appear, the dose of cysteamine should be reduced or stopped. Treatment may be restarted at a lower dose under close supervision, and then slowly titrated to the appropriate therapeutic dose (see sections 4.2). If a severe skin rash develops such as erythema multiforme bullosa or toxic epidermal necrolysis, cysteamine should not be re-administered (see sections 4.8).
\*\*Gastrointestinal\*\*
GI ulceration and bleeding have been reported in patients receiving immediate-release cysteamine bitartrate. Physicians should remain alert for signs of ulceration and bleeding and should inform patients and/or guardians about the signs and symptoms of serious GI toxicity and what steps to take if they occur.
GI tract symptoms including nausea, vomiting, anorexia and abdominal pain have been associated with cysteamine.
Strictures of the ileo-caecum and large bowel (fibrosing colonopathy) was first described in cystic fibrosis patients who were given high doses of pancreatic enzymes in the form of tablets with an enteric coating of methacrylic acid - ethyl acrylate copolymer (1:1), one of the excipients in PROCYSBI. As a precaution, unusual abdominal symptoms or changes in abdominal symptoms should be medically assessed to exclude the possibility of fibrosing colonopathy.
\*\*Central Nervous System (CNS)\*\*
CNS symptoms such as seizures, lethargy, somnolence, depression, and encephalopathy have been associated with cysteamine. If CNS symptoms develop, the patient should be carefully evaluated and the dose adjusted as necessary. Patients should not engage in potentially hazardous activities until the effects of cysteamine on mental performance are known (see section 4.7).
\*\*Leukopenia and abnormal liver function\*\*
Cysteamine has occasionally been associated with reversible leukopenia and abnormal liver function. Therefore, blood counts and liver function should be monitored.
\*\*Benign intracranial hypertension\*\*
There have been reports of benign intracranial hypertension (or pseudotumor cerebri (PTC)) and/or papilledema associated with cysteamine bitartrate treatment that has resolved with the addition of diuretic therapy (post-marketing experience with the immediate-release cysteamine bitartrate). Physicians should instruct patients to report any of the following symptoms: headache, tinnitus, dizziness, nausea, diplopia, blurred vision, loss of vision, pain behind the eye or pain with eye movement. A periodic eye examination is needed to identify this condition early and timely treatment should be provided when it occurs to prevent vision loss.
\*\*PROCYSBI contains sodium\*\*
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially “sodium-free”.4.5 Interaction with other medicinal products and other forms of interaction
It cannot be excluded that cysteamine is a clinically relevant inducer of CYP enzymes, inhibitor of P-gp and BCRP at the intestinal level and inhibitor of liver uptake transporters (OATP1B1, OATP1B3 and OCT1).
\*\*Co-administration with electrolyte and mineral replacement\*\*
Cysteamine can be administered with electrolyte (except bicarbonate) and mineral replacements necessary for management of Fanconi syndrome as well as vitamin D and thyroid hormone. Bicarbonate should be administered at least one hour before or one hour after PROCYSBI to avoid potential earlier release of cysteamine.
Indomethacin and cysteamine have been used simultaneously in some patients. In cases of patients with kidney transplants, anti-rejection treatments have been used with cysteamine.
Co-administration of the proton pump inhibitor omeprazole and PROCYSBI \*in vivo\* showed no effects on cysteamine bitartrate exposure.4.6 Fertility, pregnancy and lactation
\*\*Women of childbearing potential\*\*
Women of childbearing potential should be informed about the risk of teratogenicity and advised to use an adequate method of contraception during the course of treatment. A negative pregnancy test should be confirmed before starting treatment.
\*\*Pregnancy\*\*
There is no adequate data from the use of cysteamine in pregnant women. Studies in animals have shown reproductive toxicity, including teratogenesis (see section 5.3). The potential risk for humans is unknown. The effect on pregnancy of untreated cystinosis is also unknown. Therefore, cysteamine bitartrate should not be used during pregnancy, particularly during the first trimester, unless clearly necessary (see section 4.4).
If a pregnancy is diagnosed or planned, the treatment should be carefully reconsidered.
\*\*Breast-feeding\*\*
Cysteamine excretion in human milk is unknown. However, due to the results of animal studies in breast-feeding females and neonates (see section 5.3), breast-feeding is contra-indicated in women taking PROCYSBI (see section 4.3).
\*\*Fertility\*\*
Effects on fertility have been seenin animal studies (see section 5.3). Azoospermia has been reported in male cystinosis patients.4.7 Effects on ability to drive and use machines
Cysteamine has minor or moderate influence on the ability to drive and use machines.
Cysteamine may cause drowsiness. When starting therapy, patients should not engage in potentially hazardous activities until the effects of the medicinal product on each individual are known.4.8 Undesirable effects
\*\*Summary of the safety profile\*\*
For the immediate-release formulation of cysteamine bitartrate, approximately 35% of patients can be expected to experience adverse reactions. These mainly involve the gastrointestinal and central nervous systems. When these reactions appear at the initiation of cysteamine therapy, temporary suspension and gradual reintroduction of treatment may be effective in improving tolerance.
In clinical studies with healthy volunteers, the most frequent adverse reactions were very common GI symptoms (16%) and occurred primarily as single episodes that were mild or moderate in severity. The adverse reactions profile for healthy subjects was similar to the adverse reactions profile in patients relative to GI disorders (diarrhoea and abdominal pain).
\*\*Tabulated list of adverse reactions\*\*
The frequency of adverse reactions is defined using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1 000 to <1/100); rare (≥1/10 000 to <1/1 000); very rare (<1/10 000) and not known (cannot be estimated from available data).
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness:
\*Table 2: Adverse reactions\*
| | |
| --- | --- |
| \*\*MedDRA system organ class\*\* | \*\*\*Frequency:\* adverse reaction\*\* |
| Blood and lymphatic system disorders | \*Uncommon:\* Leukopenia |
| Immune system disorders | \*Uncommon\*: Anaphylactic reaction |
| Metabolism and nutrition disorders | \*Very common\*: Anorexia |
| Psychiatric disorders | \*Uncommon\*: Nervousness, hallucination |
| Nervous system disorders | \*Common\*: Headache, encephalopathy |
| \*Uncommon\*: Somnolence, convulsions |
| Gastrointestinal disorders | \*Very common\*: Vomiting, nausea, diarrhoea |
| \*Common\*: Abdominal pain, breath odour, dyspepsia, gastroenteritis |
| \*Uncommon\*: Gastrointestinal ulcer |
| Skin and subcutaneous tissue disorders | \*Common\*: Skin odour abnormal, rash |
| \*Uncommon\*: Hair colour changes, skin striae, skin fragility (molluscoid pseudotumour on elbows) |
| Musculoskeletal and connective tissue disorders | \*Uncommon\*: Joint hyperextension, leg pain, genu valgum, osteopenia, compression fracture, scoliosis. |
| Renal and urinary disorders | \*Uncommon\*: Nephrotic syndrome |
| General disorders and administration site conditions | \*Very common\*: Lethargy, pyrexia |
| \*Common\*: Asthenia |
| Investigations | \*Common\*: Liver function tests abnormal |
\*\*Description of selected adverse reactions\*\*
\*\*\*Clinical studies experience with PROCYSBI\*\*\*
In clinical studies comparing PROCYSBI to the immediate-release cysteamine bitartrate, one third of the patients exhibited very common GI disorders (nausea, vomiting, abdominal pain). Common nervous system disorders (headache, somnolence and lethargy) and common general disorders (asthenia) were also seen.
\*\*\*Post-marketing experience with immediate-release cysteamine bitartrate\*\*\*
Benign intracranial hypertension (or pseudotumor cerebri (PTC)) with papilledema; skin lesions, molluscoid pseudotumors, skin striae, skin fragility; joint hyperextension, leg pain, genu valgum, osteopenia, compression fracture and scoliosis have been reported with immediate-release cysteamine bitartrate (see section 4.4).
Two cases of nephrotic syndrome have been reported within 6 months of starting therapy with progressive recovery after treatment discontinuation. Histology showed a membranous glomerulonephritis of the renal allograft in one case and hypersensitivity interstitial nephritis in the other.
A few cases of Ehlers-Danlos-like syndrome on elbows have been reported in children chronically treated with high doses of different cysteamine preparations (cysteamine chlorhydrate or cystamine or cysteamine bitartrate) mostly above the maximal dose 1.95 g/m2/day. In some cases, these skin lesions were associated with skin striae and bone lesions first seen during an X-ray examination. Bone disorders reported were genu valgum, leg pain and hyperextensive joints, osteopenia, compression fractures, and scoliosis. In the few cases where histopathological examination of the skin was performed, the results suggested angioendotheliomatosis. One patient subsequently died of acute cerebral ischemia with marked vasculopathy. In some patients, the skin lesions on elbows regressed after immediate-release cysteamine dose reduction (see section 4.4).
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:
Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
An overdose of cysteamine may cause progressive lethargy.
Should overdosing occur, the respiratory and cardiovascular systems should be supported appropriately. No specific antidote is known. It is not known if cysteamine is removed by haemodialysis.
- Instruction Pharmacology
- 5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Other alimentary tract and metabolism product, amino acids and derivatives, ATC code: A16AA04.
Cysteamine is the simplest stable aminothiol and a degradation product of the amino acid cysteine. Cysteamine participates within lysosomes in a thiol-disulfide interchange reaction converting cystine into cysteine and cysteine-cysteamine mixed disulfide, both of which can exit the lysosome in patients with cystinosis.
Normal individuals and persons heterozygous for cystinosis have white blood cell cystine levels of < 0.2 and usually below 1 nmol hemicystine/mg protein, respectively, when measured using the mixed leukocyte assay. Individuals with cystinosis have elevations of WBC cystine above 2 nmol hemicystine/mg protein.
WBC cystine is monitored in these patients to determine adequacy of dosing, levels being measured 30 minutes after dosing when treated with PROCYSBI.
A pivotal phase 3 randomised, crossover PK and PD study (which was also the first ever randomised study with immediate-release cysteamine bitartrate) demonstrated that at steady-state, patients receiving PROCYSBI every 12 hours (Q12H) maintained a comparable depletion of WBC cystine levels compared to immediate-release cysteamine bitartrate every 6 hours (Q6H). Forty-three (43) patients were randomised; twenty-seven (27) children (ages 6 to 12 years old), fifteen (15) adolescents (ages 12 to 21 years old) and one (1) adult with cystinosis and with native kidney function based on an estimated glomerular filtration rate (GFR) (corrected for body surface area) > 30 mL/minute/1.73 m2 were randomised. Of those forty-three (43) patients, two (2) siblings withdrew at the end of the first crossover period, due to a prior planned surgery in one (1) of them; forty-one (41) patients completed the protocol. Two (2) patients were excluded from the per-protocol analysis because their WBC cystine level increased over 2 nmol hemicystine/mg protein during the immediate-release cysteamine treatment period. Thirty-nine (39) patients were included in the final primary per protocol efficacy analysis.
\*Table 3: Comparison of WBC cystine levels following administration of immediate-release cysteamine bitartrate and PROCYSBI\*
| | | |
| --- | --- | --- |
| \*\*Per –Protocol (PP) Population (N=39)\*\* | | |
| | Immediate-release cysteamine bitartrate | PROCYSBI |
| WBC cystine level (LS Mean ± SE) in nmol hemicystine/mg protein\\* | 0.44 ± 0.05 | 0.51 ± 0.05 |
| Treatment effect (LS mean ± SE; 95.8% CI; p-value) | 0.08 ± 0.03; 0.01 to 0.15; <0.0001 | |
| \*\*All Evaluable Patients (ITT) Population (N=41)\*\* | | |
| | Immediate-release cysteamine bitartrate | PROCYSBI |
| WBC cystine level (LS Mean ± SE) in nmol hemicystine/mg protein\\* | 0.74 ± 0.14 | 0.53 ± 0.14 |
| Treatment effect (LS mean ± SE; 95.8% CI; p-value) | -0.21 ± 0.14; -0.48 to 0.06; <0.001 | |
\\*Measured using the mixed leukocyte assay
Forty of forty-one (40/41) patients who completed the pivotal phase 3 study were entered in a prospective study with PROCYSBI that stayed open as long as PROCYSBI could not be prescribed by their treating physician. In this study, the WBC cystine measured using the mixed leukocyte assay was always on average under optimal control at < 1 nmol hemicystine/mg protein. The estimated glomerular filtration rate (eGFR) did not change for the study population over time.5.2 Pharmacokinetic properties
\*\*Absorption\*\*
The relative bioavailability is about 125% as compared to immediate-release cysteamine.
Food intake reduces the absorption of PROCYSBI at 30 minutes pre-dose (approximately 35% decrease in exposure) and at 30 min post-dose (approximately 16 or 45% decrease in exposure for intact and open capsules respectively). Food intake two hours after administration did not affect the absorption of PROCYSBI.
\*\*Distribution\*\*
The \*in vitro\* plasma protein binding of cysteamine, primarily to albumin, is approximately 54% andindependent of plasma drug concentration over the therapeutic range.
\*\*Biotransformation\*\*
The elimination of unchanged cysteamine in the urine has been shown to range between 0.3% and 1.7% of the total daily dose in four patients; the bulk of cysteamine is excreted as sulphate.
\*In vitro\* data suggests that cysteamine bitartrate is likely to be metabolised by multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP2E1. CYP2A6 and CYP3A4 were not involved in the metabolism of cysteamine bitartrate under the experimental conditions.
\*\*Elimination\*\*
The terminal half-life of cysteamine bitartrate is approximately 4 hours.
Cysteamine bitartrate is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4 \*in vitro\*.
\*In vitro\*: Cysteamine bitartrate is a substrate of P-gp and OCT2, but not a substrate of BCRP, OATP1B1, OATP1B3, OAT1, OAT3 and OCT1. Cysteamine bitartrate is not an inhibitor of OAT1, OAT3 and OCT2.
\*\*Special populations\*\*
The pharmacokinetics of cysteamine bitartrate has not been studied in special populations.5.3 Preclinical safety data
In genotoxicity studies published for cysteamine, induction of chromosome aberrations in cultured eukaryotic cell lines has been reported. Specific studies with cysteamine did not show any mutagenic effects in the Ames test or any clastogenic effect in the mouse micronucleus test. A bacterial reverse mutation assay study (“Ames test”) was performed with the cysteamine bitartrate used for PROCYSBI and cysteamine bitartrate did not show any mutagenic effects in this test.
Reproduction studies showed embryo-foetotoxic effects (resorptions and post-implantation losses) in rats at the 100 mg/kg/day dose level and in rabbits receiving cysteamine 50 mg/kg/day. Teratogenic effects have been described in rats when cysteamine is administered over the period of organogenesis at a dose of 100 mg/kg/day.
This is equivalent to 0.6 g/m2/day in the rat, which is slightly less than the recommended clinical maintenance dose of cysteamine, i.e. 1.3 g/m2/day. A reduction of fertility was observed in rats at 375 mg/kg/day, a dose at which body weight gain was retarded. At this dose, weight gain and survival of the offspring during lactation was also reduced. High doses of cysteamine impair the ability of lactating mothers to feed their pups. Single doses of the drug inhibit prolactin secretion in animals.
Administration of cysteamine in neonate rats induced cataracts.
High doses of cysteamine, either by oral or parenteral routes, produce duodenal ulcers in rats and mice but not in monkeys. Experimental administration of the drug causes depletion of somatostatin in several animal species. The consequence of this for the clinical use of the drug is unknown.
No carcinogenic studies have been conducted with cysteamine bitartrate gastro-resistant hard capsules.
- Instruction Pharmaceutical Particulars
- 6.1 List of excipients
\*\*Capsule content\*\*
microcrystalline cellulose
methacrylic acid \*\*\*-\*\*\* ethyl acrylate copolymer (1:1)
hypromellose
talc
triethyl citrate
sodium lauryl sulphate
\*\*Capsule shell\*\*
gelatin
titanium dioxide (E171)
indigo carmine (E132)
\*\*Printing ink\*\*
shellac
povidone K-17
titanium dioxide (E171)6.2 Incompatibilities
Not applicable.6.3 Shelf life
2 years
In-use shelf life: 30 days.6.4 Special precautions for storage
Store in a refrigerator (2°C-8°C). Do not freeze.
Keep the container tightly closed in order to protect from light and moisture.
After opening do not store above 25°C.6.5 Nature and contents of container
\*\*PROCYSBI 25 mg gastro-resistant hard capsule\*\*
50 mL white HDPE bottle containing 60 gastro-resistant hard capsules with one 2-in-1 desiccant cylinder and one oxygen absorber cylinder, with a child resistant polypropylene closure.
Each bottle contains two plastic cylinders used for additional moisture and air protection.
Please keep the two cylinders in each bottle during the use of the bottle. The cylinders may be discarded with the bottle after use.
\*\*PROCYSBI 75 mg gastro-resistant hard capsule\*\*
400 mL white HDPE bottle containing 250 gastro-resistant hard capsules with one 2-in-1 desiccant cylinder and two oxygen absorber cylinders, with a child resistant polypropylene closure.
Each bottle contains three plastic cylinders used for additional moisture and air protection.
Please keep the three cylinders in each bottle during the use of the bottle. The cylinders may be discarded with the bottle after use.6.6 Special precautions for disposal and other handling
\*\*Handling\*\*
\*\*\*Sprinkling on food\*\*\*
Capsules for either the morning or evening dose should be opened and the contents sprinkled onto approximately 100 grams of apple sauce or fruit jam. Gently stir the contents into the soft food, creating a mixture of cysteamine granules and food. The entire amount of the mixture should be eaten. This may be followed by 250 mL of an acceptable acidic liquid - fruit juice (e.g., orange juice or any acidic fruit juice) or water. The mixture must be eaten within 2 hours after preparation and may be refrigerated from the time of preparation to the time of administration.
\*\*\*Administering through feeding tubes\*\*\*
Capsules for either the morning or evening dose should be opened and the contents sprinkled onto approximately 100 grams of apple sauce or fruit jam. Gently stir the contents into the soft food, creating a mixture of cysteamine granules and the soft food. The mixture should then be administered via gastrostomy tube, nasogastric tube or gastrostomy-jejunostomy tube using a catheter tip syringe. Before PROCYSBI administration: Unclasp the G-tube button and attach the feeding tube. Flush with 5 mL of water to clear the button. Draw the mixture up into the syringe. A maximum 60 mL mixture volume in a catheter tip syringe is recommended for use with a straight or bolus feeding tube. Place the opening of the syringe containing the PROCYSBI/apple sauce/fruit jam mixture into the opening of the feeding tube and fill completely with the mixture: pressing gently on the syringe and keeping the feeding tube horizontal during administration can help to avoid clogging issues. Using a viscous food such as apple sauce or fruit jam at a rate of about 10 mL every 10 seconds until the syringe is completely empty, is also suggested to avoid clogging. Repeat the above step until all of the mixture is given. After PROCYSBI administration, draw 10 mL of fruit juice or water up into another syringe and flush the G-tube ensuring that none of the apple sauce/fruit jam and granules mixture gets stuck on the G-tube.
The mixture must be administered within 2 hours after preparation and may be refrigerated from the time of preparation to the time of administration. Nothing of the mixture should be saved.
\*\*\*Sprinkling in orange juice or any acidic fruit juice or water\*\*\*
Capsules for either the morning or evening dose should be opened and the contents sprinkled into 100 to 150 mL of acidic fruit juice or water. Dose administration options are provided below:
• Option 1/Syringe: Mix gently for 5 minutes, then aspirate the mixture of cysteamine granules and acidic fruit juice or water into a dosing syringe.
• Option 2/Cup: Mix gently for 5 minutes in a cup or shake gently for 5 minutes in a covered cup (e.g., “sippy” cup). Drink the mixture of cysteamine granules and acidic fruit juice or water.
The mixture must be administered (drunk) within 30 minutes after preparation and may be refrigerated from the time of preparation to the time of administration.
\*\*Disposal\*\*
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
- Instruction Content
- ## Composition
\*\*PROCYSBI 25 mg gastro-resistant hard capsule\*\*
Each gastro-resistant hard capsule contains 25 mg of cysteamine (as mercaptamine bitartrate).
\*\*PROCYSBI 75 mg gastro-resistant hard capsule\*\*
Each gastro-resistant hard capsule contains 75 mg of cysteamine (as mercaptamine bitartrate).
For the full list of excipients, see section 6.1.
## Pharmaceutical Form
Gastro-resistant hard capsule.
\*\*PROCYSBI 25 mg\*\* \*\*gastro-resistant hard capsule\*\*
Light blue size 3 (15.9 x 5.8 mm) hard capsules imprinted “25 mg” in white ink and a light blue cap imprinted with “PRO” in white ink.
\*\*PROCYSBI 75 mg gastro-resistant hard capsule\*\*
Light blue size 0 (21.7 x 7.6 mm) hard capsules imprinted “75 mg” in white ink and a dark blue cap imprinted with “PRO” in white ink.
## Clinical Particulars
4.1 Therapeutic indications
PROCYSBI is indicated for the treatment of proven nephropathic cystinosis. Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.4.2 Posology and method of administration
PROCYSBI treatment should be initiated under the supervision of a physician experienced in the treatment of cystinosis.
Cysteamine therapy must be initiated promptly once the diagnosis is confirmed (i.e., increased WBC cystine) to achieve maximum benefit.
\*\*Posology\*\*
White blood cell (WBC) cystine concentration may for instance be measured by a number of different techniques such as specific WBC subsets (e.g., granulocyte assay) or the mixed leukocyte assay with each assay having different target values. Healthcare professionals should refer to the assay-specific therapeutic targets provided by individual testing laboratories when making decisions regarding diagnosis and PROCYSBI dosing for cystinosis patients. For example the therapeutic goal is to maintain a WBC cystine level < 1 nmol hemicystine/mg protein (when measured using the mixed leukocyte assay), 30 min after dosing For patients adherent to a stable dose of PROCYSBI, and who do not have easy access to an adequate facility for measuring their WBC cystine, the goal of therapy should be to maintain plasma cysteamine concentration > 0.1 mg/L, 30 min after dosing.
Measurement timing: PROCYSBI should be administered every 12 hours. The determination of WBC cystine and/or plasma cysteamine must be obtained 12.5 hours after the evening dose the day before, and therefore 30 minutes after the following morning dose is given.
\*\*\*Transferring patients from immediate-release cysteamine bitartrate hard capsules\*\*\*
Patients with cystinosis taking immediate-release cysteamine bitartrate may be transferred to a total daily dose of PROCYSBI equal to their previous total daily dose of immediate-release cysteamine bitartrate. Total daily dose should be divided by two and administered every 12 hours. The maximum recommended dose of cysteamine is 1.95 g/m2/day. The use of doses higher than 1.95 g/m2/day is not recommended (see section 4.4).
Patients being transferred from immediate-release cysteamine bitartrate to PROCYSBI should have their WBC cystine levels measured in 2 weeks, and thereafter every 3 months to assess optimal dose as described above.
\*\*\*Newly diagnosed adult patients\*\*\*
Newly diagnosed adult patients should be started on 1/6 to 1/4 of the targeted maintenance dose of PROCYSBI. The targeted maintenance dose is 1.3 g/m2/day, in two divided doses, given every 12 hours (see below table 1). The dose should be raised if there is adequate tolerance and the WBC cystine level remains > 1 nmol hemicystine/mg protein (when measured using the mixed leukocyte assay). The maximum recommended dose of cysteamine is 1.95 g/m2/day. The use of doses higher than 1.95 g/m2/day is not recommended (see section 4.4).
The target values provided in the SmPC are obtained from using the mixed leucocyte assay. It should be noted that therapeutic targets for cystine depletion are assay-specific and different assays have specific treatment targets. Therefore, healthcare professionals should refer to the assay-specific therapeutic targets provided by individual testing laboratories.
\*\*\*Newly diagnosed paediatric population\*\*\*
The targeted maintenance dose of 1.3 g/m2/day can be approximated according to the following table, which takes surface area as well as weight into consideration.
\*Table 1: Recommended dose\*
| | |
| --- | --- |
| \*\*Weight in kilograms\*\* | \*\*Recommended dose in mg\*\* \*\*Every 12 hours\\*\*\* |
| 0–5 | 200 |
| 5–10 | 300 |
| 11–15 | 400 |
| 16–20 | 500 |
| 21–25 | 600 |
| 26–30 | 700 |
| 31–40 | 800 |
| 41–50 | 900 |
| >50 | 1 000 |
\\*Higher dose may be required to achieve target WBC cystine concentration.
The use of doses higher than 1.95 g/m2/day is not recommended.
\*\*\*Missed doses\*\*\*
If a dose is missed, it should be taken as soon as possible. If it is within four hours of the next dose, the missed dose should be skipped going back to the regular dosing schedule. The dose should not be doubled.
\*\*\*Special populations\*\*\*
\*Patients with poor tolerability\*
Patients with poorer tolerability still receive significant benefit if white blood cell cystine levels are below 2 nmol hemicystine/mg protein (when measured using the mixed leukocyte assay). The cysteamine dose can be increased to a maximum of 1.95 g/m2/day to achieve this level. The dose of 1.95 g/m2/day of immediate-release cysteamine bitartrate has been associated with an increased rate of withdrawal from treatment due to intolerance and an increased incidence of adverse events. If cysteamine is initially poorly tolerated due to gastrointestinal (GI) tract symptoms or transient skin rashes, therapy should be temporarily stopped, then re-instituted at a lower dose and gradually increased to the appropriate dose (see section 4.4).
\*Patients on dialysis or post-transplantation\*
Experience has occasionally shown that some forms of cysteamine are less well tolerated (i.e. leading to more adverse events) when patients are on dialysis. A closer monitoring of the WBC cystine levels is recommended in these patients.
\*Patients with renal impairment\*
Dose adjustment is not normally required; however, WBC cystine levels should be monitored.
\*Patients with hepatic impairment\*
Dose adjustment is not normally required; however, WBC cystine levels should be monitored.
\*\*Method of administration\*\*
Oral use.
This medicinal product can be administered by swallowing the intact capsules as well as sprinkling the capsule contents (enteric coated beads) on food or delivery through a gastric feeding tube.
Do not crush or chew capsules or capsule contents.
\*\*\*Administration with food\*\*\*
Cysteamine bitartrate can be administered with an acidic fruit juice or water.
Cysteamine bitartrate should not be administered with food rich in fat or proteins, or with frozen food like ice-cream. Patients should try to consistently avoid meals and dairy products for at least 1 hour before and 1 hour after PROCYSBI dosing. If fasting during this period is not possible, it is acceptable to eat only a small amount (~ 100 grams) of food (preferentially carbohydrates) during the hour before and after PROCYSBI administration. It is important to dose PROCYSBI in relation to food intake in a consistent and reproducible way over time (see section 5.2).
In paediatric patients who are at risk of aspiration, aged approximately 6 years and under, the hard capsules should be opened and the content sprinkled on food or liquid listed in section 6.6.
For instructions about the medicinal product before administration, see section 6.6.4.3 Contraindications
• Hypersensitivity to the active substance, any form of cysteamine (mercaptamine), or to any of the excipients listed in section 6.1.
• Hypersensitivity to penicillamine.
• Breast-feeding.4.4 Special warnings and precautions for use
The use of doses higher than 1.95 g/m2/day is not recommended (see section 4.2).
Oral cysteamine has not been shown to prevent eye deposition of cystine crystals. Therefore, where cysteamine ophthalmic solution is used for that purpose, its usage should continue.
If a pregnancy is diagnosed or planned, the treatment should be carefully reconsidered and the patient must be advised of the possible teratogenic risk of cysteamine (see section 4.6).
Intact capsules of PROCYSBI should not be administered to children under the age of approximately 6 years due to risk of aspiration (see section 4.2).
\*\*Dermatological\*\*
There have been reports of serious skin lesions in patients treated with high doses of immediate-release cysteamine bitartrate or other cysteamine salts that have responded to cysteamine dose reduction. Physicians should routinely monitor the skin and bones of patients receiving cysteamine.
If skin or bone abnormalities appear, the dose of cysteamine should be reduced or stopped. Treatment may be restarted at a lower dose under close supervision, and then slowly titrated to the appropriate therapeutic dose (see sections 4.2). If a severe skin rash develops such as erythema multiforme bullosa or toxic epidermal necrolysis, cysteamine should not be re-administered (see sections 4.8).
\*\*Gastrointestinal\*\*
GI ulceration and bleeding have been reported in patients receiving immediate-release cysteamine bitartrate. Physicians should remain alert for signs of ulceration and bleeding and should inform patients and/or guardians about the signs and symptoms of serious GI toxicity and what steps to take if they occur.
GI tract symptoms including nausea, vomiting, anorexia and abdominal pain have been associated with cysteamine.
Strictures of the ileo-caecum and large bowel (fibrosing colonopathy) was first described in cystic fibrosis patients who were given high doses of pancreatic enzymes in the form of tablets with an enteric coating of methacrylic acid - ethyl acrylate copolymer (1:1), one of the excipients in PROCYSBI. As a precaution, unusual abdominal symptoms or changes in abdominal symptoms should be medically assessed to exclude the possibility of fibrosing colonopathy.
\*\*Central Nervous System (CNS)\*\*
CNS symptoms such as seizures, lethargy, somnolence, depression, and encephalopathy have been associated with cysteamine. If CNS symptoms develop, the patient should be carefully evaluated and the dose adjusted as necessary. Patients should not engage in potentially hazardous activities until the effects of cysteamine on mental performance are known (see section 4.7).
\*\*Leukopenia and abnormal liver function\*\*
Cysteamine has occasionally been associated with reversible leukopenia and abnormal liver function. Therefore, blood counts and liver function should be monitored.
\*\*Benign intracranial hypertension\*\*
There have been reports of benign intracranial hypertension (or pseudotumor cerebri (PTC)) and/or papilledema associated with cysteamine bitartrate treatment that has resolved with the addition of diuretic therapy (post-marketing experience with the immediate-release cysteamine bitartrate). Physicians should instruct patients to report any of the following symptoms: headache, tinnitus, dizziness, nausea, diplopia, blurred vision, loss of vision, pain behind the eye or pain with eye movement. A periodic eye examination is needed to identify this condition early and timely treatment should be provided when it occurs to prevent vision loss.
\*\*PROCYSBI contains sodium\*\*
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially “sodium-free”.4.5 Interaction with other medicinal products and other forms of interaction
It cannot be excluded that cysteamine is a clinically relevant inducer of CYP enzymes, inhibitor of P-gp and BCRP at the intestinal level and inhibitor of liver uptake transporters (OATP1B1, OATP1B3 and OCT1).
\*\*Co-administration with electrolyte and mineral replacement\*\*
Cysteamine can be administered with electrolyte (except bicarbonate) and mineral replacements necessary for management of Fanconi syndrome as well as vitamin D and thyroid hormone. Bicarbonate should be administered at least one hour before or one hour after PROCYSBI to avoid potential earlier release of cysteamine.
Indomethacin and cysteamine have been used simultaneously in some patients. In cases of patients with kidney transplants, anti-rejection treatments have been used with cysteamine.
Co-administration of the proton pump inhibitor omeprazole and PROCYSBI \*in vivo\* showed no effects on cysteamine bitartrate exposure.4.6 Fertility, pregnancy and lactation
\*\*Women of childbearing potential\*\*
Women of childbearing potential should be informed about the risk of teratogenicity and advised to use an adequate method of contraception during the course of treatment. A negative pregnancy test should be confirmed before starting treatment.
\*\*Pregnancy\*\*
There is no adequate data from the use of cysteamine in pregnant women. Studies in animals have shown reproductive toxicity, including teratogenesis (see section 5.3). The potential risk for humans is unknown. The effect on pregnancy of untreated cystinosis is also unknown. Therefore, cysteamine bitartrate should not be used during pregnancy, particularly during the first trimester, unless clearly necessary (see section 4.4).
If a pregnancy is diagnosed or planned, the treatment should be carefully reconsidered.
\*\*Breast-feeding\*\*
Cysteamine excretion in human milk is unknown. However, due to the results of animal studies in breast-feeding females and neonates (see section 5.3), breast-feeding is contra-indicated in women taking PROCYSBI (see section 4.3).
\*\*Fertility\*\*
Effects on fertility have been seenin animal studies (see section 5.3). Azoospermia has been reported in male cystinosis patients.4.7 Effects on ability to drive and use machines
Cysteamine has minor or moderate influence on the ability to drive and use machines.
Cysteamine may cause drowsiness. When starting therapy, patients should not engage in potentially hazardous activities until the effects of the medicinal product on each individual are known.4.8 Undesirable effects
\*\*Summary of the safety profile\*\*
For the immediate-release formulation of cysteamine bitartrate, approximately 35% of patients can be expected to experience adverse reactions. These mainly involve the gastrointestinal and central nervous systems. When these reactions appear at the initiation of cysteamine therapy, temporary suspension and gradual reintroduction of treatment may be effective in improving tolerance.
In clinical studies with healthy volunteers, the most frequent adverse reactions were very common GI symptoms (16%) and occurred primarily as single episodes that were mild or moderate in severity. The adverse reactions profile for healthy subjects was similar to the adverse reactions profile in patients relative to GI disorders (diarrhoea and abdominal pain).
\*\*Tabulated list of adverse reactions\*\*
The frequency of adverse reactions is defined using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1 000 to <1/100); rare (≥1/10 000 to <1/1 000); very rare (<1/10 000) and not known (cannot be estimated from available data).
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness:
\*Table 2: Adverse reactions\*
| | |
| --- | --- |
| \*\*MedDRA system organ class\*\* | \*\*\*Frequency:\* adverse reaction\*\* |
| Blood and lymphatic system disorders | \*Uncommon:\* Leukopenia |
| Immune system disorders | \*Uncommon\*: Anaphylactic reaction |
| Metabolism and nutrition disorders | \*Very common\*: Anorexia |
| Psychiatric disorders | \*Uncommon\*: Nervousness, hallucination |
| Nervous system disorders | \*Common\*: Headache, encephalopathy |
| \*Uncommon\*: Somnolence, convulsions |
| Gastrointestinal disorders | \*Very common\*: Vomiting, nausea, diarrhoea |
| \*Common\*: Abdominal pain, breath odour, dyspepsia, gastroenteritis |
| \*Uncommon\*: Gastrointestinal ulcer |
| Skin and subcutaneous tissue disorders | \*Common\*: Skin odour abnormal, rash |
| \*Uncommon\*: Hair colour changes, skin striae, skin fragility (molluscoid pseudotumour on elbows) |
| Musculoskeletal and connective tissue disorders | \*Uncommon\*: Joint hyperextension, leg pain, genu valgum, osteopenia, compression fracture, scoliosis. |
| Renal and urinary disorders | \*Uncommon\*: Nephrotic syndrome |
| General disorders and administration site conditions | \*Very common\*: Lethargy, pyrexia |
| \*Common\*: Asthenia |
| Investigations | \*Common\*: Liver function tests abnormal |
\*\*Description of selected adverse reactions\*\*
\*\*\*Clinical studies experience with PROCYSBI\*\*\*
In clinical studies comparing PROCYSBI to the immediate-release cysteamine bitartrate, one third of the patients exhibited very common GI disorders (nausea, vomiting, abdominal pain). Common nervous system disorders (headache, somnolence and lethargy) and common general disorders (asthenia) were also seen.
\*\*\*Post-marketing experience with immediate-release cysteamine bitartrate\*\*\*
Benign intracranial hypertension (or pseudotumor cerebri (PTC)) with papilledema; skin lesions, molluscoid pseudotumors, skin striae, skin fragility; joint hyperextension, leg pain, genu valgum, osteopenia, compression fracture and scoliosis have been reported with immediate-release cysteamine bitartrate (see section 4.4).
Two cases of nephrotic syndrome have been reported within 6 months of starting therapy with progressive recovery after treatment discontinuation. Histology showed a membranous glomerulonephritis of the renal allograft in one case and hypersensitivity interstitial nephritis in the other.
A few cases of Ehlers-Danlos-like syndrome on elbows have been reported in children chronically treated with high doses of different cysteamine preparations (cysteamine chlorhydrate or cystamine or cysteamine bitartrate) mostly above the maximal dose 1.95 g/m2/day. In some cases, these skin lesions were associated with skin striae and bone lesions first seen during an X-ray examination. Bone disorders reported were genu valgum, leg pain and hyperextensive joints, osteopenia, compression fractures, and scoliosis. In the few cases where histopathological examination of the skin was performed, the results suggested angioendotheliomatosis. One patient subsequently died of acute cerebral ischemia with marked vasculopathy. In some patients, the skin lesions on elbows regressed after immediate-release cysteamine dose reduction (see section 4.4).
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:
Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
An overdose of cysteamine may cause progressive lethargy.
Should overdosing occur, the respiratory and cardiovascular systems should be supported appropriately. No specific antidote is known. It is not known if cysteamine is removed by haemodialysis.
## Pharmacological Properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Other alimentary tract and metabolism product, amino acids and derivatives, ATC code: A16AA04.
Cysteamine is the simplest stable aminothiol and a degradation product of the amino acid cysteine. Cysteamine participates within lysosomes in a thiol-disulfide interchange reaction converting cystine into cysteine and cysteine-cysteamine mixed disulfide, both of which can exit the lysosome in patients with cystinosis.
Normal individuals and persons heterozygous for cystinosis have white blood cell cystine levels of < 0.2 and usually below 1 nmol hemicystine/mg protein, respectively, when measured using the mixed leukocyte assay. Individuals with cystinosis have elevations of WBC cystine above 2 nmol hemicystine/mg protein.
WBC cystine is monitored in these patients to determine adequacy of dosing, levels being measured 30 minutes after dosing when treated with PROCYSBI.
A pivotal phase 3 randomised, crossover PK and PD study (which was also the first ever randomised study with immediate-release cysteamine bitartrate) demonstrated that at steady-state, patients receiving PROCYSBI every 12 hours (Q12H) maintained a comparable depletion of WBC cystine levels compared to immediate-release cysteamine bitartrate every 6 hours (Q6H). Forty-three (43) patients were randomised; twenty-seven (27) children (ages 6 to 12 years old), fifteen (15) adolescents (ages 12 to 21 years old) and one (1) adult with cystinosis and with native kidney function based on an estimated glomerular filtration rate (GFR) (corrected for body surface area) > 30 mL/minute/1.73 m2 were randomised. Of those forty-three (43) patients, two (2) siblings withdrew at the end of the first crossover period, due to a prior planned surgery in one (1) of them; forty-one (41) patients completed the protocol. Two (2) patients were excluded from the per-protocol analysis because their WBC cystine level increased over 2 nmol hemicystine/mg protein during the immediate-release cysteamine treatment period. Thirty-nine (39) patients were included in the final primary per protocol efficacy analysis.
\*Table 3: Comparison of WBC cystine levels following administration of immediate-release cysteamine bitartrate and PROCYSBI\*
| | | |
| --- | --- | --- |
| \*\*Per –Protocol (PP) Population (N=39)\*\* | | |
| | Immediate-release cysteamine bitartrate | PROCYSBI |
| WBC cystine level (LS Mean ± SE) in nmol hemicystine/mg protein\\* | 0.44 ± 0.05 | 0.51 ± 0.05 |
| Treatment effect (LS mean ± SE; 95.8% CI; p-value) | 0.08 ± 0.03; 0.01 to 0.15; <0.0001 | |
| \*\*All Evaluable Patients (ITT) Population (N=41)\*\* | | |
| | Immediate-release cysteamine bitartrate | PROCYSBI |
| WBC cystine level (LS Mean ± SE) in nmol hemicystine/mg protein\\* | 0.74 ± 0.14 | 0.53 ± 0.14 |
| Treatment effect (LS mean ± SE; 95.8% CI; p-value) | -0.21 ± 0.14; -0.48 to 0.06; <0.001 | |
\\*Measured using the mixed leukocyte assay
Forty of forty-one (40/41) patients who completed the pivotal phase 3 study were entered in a prospective study with PROCYSBI that stayed open as long as PROCYSBI could not be prescribed by their treating physician. In this study, the WBC cystine measured using the mixed leukocyte assay was always on average under optimal control at < 1 nmol hemicystine/mg protein. The estimated glomerular filtration rate (eGFR) did not change for the study population over time.5.2 Pharmacokinetic properties
\*\*Absorption\*\*
The relative bioavailability is about 125% as compared to immediate-release cysteamine.
Food intake reduces the absorption of PROCYSBI at 30 minutes pre-dose (approximately 35% decrease in exposure) and at 30 min post-dose (approximately 16 or 45% decrease in exposure for intact and open capsules respectively). Food intake two hours after administration did not affect the absorption of PROCYSBI.
\*\*Distribution\*\*
The \*in vitro\* plasma protein binding of cysteamine, primarily to albumin, is approximately 54% andindependent of plasma drug concentration over the therapeutic range.
\*\*Biotransformation\*\*
The elimination of unchanged cysteamine in the urine has been shown to range between 0.3% and 1.7% of the total daily dose in four patients; the bulk of cysteamine is excreted as sulphate.
\*In vitro\* data suggests that cysteamine bitartrate is likely to be metabolised by multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP2E1. CYP2A6 and CYP3A4 were not involved in the metabolism of cysteamine bitartrate under the experimental conditions.
\*\*Elimination\*\*
The terminal half-life of cysteamine bitartrate is approximately 4 hours.
Cysteamine bitartrate is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4 \*in vitro\*.
\*In vitro\*: Cysteamine bitartrate is a substrate of P-gp and OCT2, but not a substrate of BCRP, OATP1B1, OATP1B3, OAT1, OAT3 and OCT1. Cysteamine bitartrate is not an inhibitor of OAT1, OAT3 and OCT2.
\*\*Special populations\*\*
The pharmacokinetics of cysteamine bitartrate has not been studied in special populations.5.3 Preclinical safety data
In genotoxicity studies published for cysteamine, induction of chromosome aberrations in cultured eukaryotic cell lines has been reported. Specific studies with cysteamine did not show any mutagenic effects in the Ames test or any clastogenic effect in the mouse micronucleus test. A bacterial reverse mutation assay study (“Ames test”) was performed with the cysteamine bitartrate used for PROCYSBI and cysteamine bitartrate did not show any mutagenic effects in this test.
Reproduction studies showed embryo-foetotoxic effects (resorptions and post-implantation losses) in rats at the 100 mg/kg/day dose level and in rabbits receiving cysteamine 50 mg/kg/day. Teratogenic effects have been described in rats when cysteamine is administered over the period of organogenesis at a dose of 100 mg/kg/day.
This is equivalent to 0.6 g/m2/day in the rat, which is slightly less than the recommended clinical maintenance dose of cysteamine, i.e. 1.3 g/m2/day. A reduction of fertility was observed in rats at 375 mg/kg/day, a dose at which body weight gain was retarded. At this dose, weight gain and survival of the offspring during lactation was also reduced. High doses of cysteamine impair the ability of lactating mothers to feed their pups. Single doses of the drug inhibit prolactin secretion in animals.
Administration of cysteamine in neonate rats induced cataracts.
High doses of cysteamine, either by oral or parenteral routes, produce duodenal ulcers in rats and mice but not in monkeys. Experimental administration of the drug causes depletion of somatostatin in several animal species. The consequence of this for the clinical use of the drug is unknown.
No carcinogenic studies have been conducted with cysteamine bitartrate gastro-resistant hard capsules.
## Pharmaceutical Particulars
6.1 List of excipients
\*\*Capsule content\*\*
microcrystalline cellulose
methacrylic acid \*\*\*-\*\*\* ethyl acrylate copolymer (1:1)
hypromellose
talc
triethyl citrate
sodium lauryl sulphate
\*\*Capsule shell\*\*
gelatin
titanium dioxide (E171)
indigo carmine (E132)
\*\*Printing ink\*\*
shellac
povidone K-17
titanium dioxide (E171)6.2 Incompatibilities
Not applicable.6.3 Shelf life
2 years
In-use shelf life: 30 days.6.4 Special precautions for storage
Store in a refrigerator (2°C-8°C). Do not freeze.
Keep the container tightly closed in order to protect from light and moisture.
After opening do not store above 25°C.6.5 Nature and contents of container
\*\*PROCYSBI 25 mg gastro-resistant hard capsule\*\*
50 mL white HDPE bottle containing 60 gastro-resistant hard capsules with one 2-in-1 desiccant cylinder and one oxygen absorber cylinder, with a child resistant polypropylene closure.
Each bottle contains two plastic cylinders used for additional moisture and air protection.
Please keep the two cylinders in each bottle during the use of the bottle. The cylinders may be discarded with the bottle after use.
\*\*PROCYSBI 75 mg gastro-resistant hard capsule\*\*
400 mL white HDPE bottle containing 250 gastro-resistant hard capsules with one 2-in-1 desiccant cylinder and two oxygen absorber cylinders, with a child resistant polypropylene closure.
Each bottle contains three plastic cylinders used for additional moisture and air protection.
Please keep the three cylinders in each bottle during the use of the bottle. The cylinders may be discarded with the bottle after use.6.6 Special precautions for disposal and other handling
\*\*Handling\*\*
\*\*\*Sprinkling on food\*\*\*
Capsules for either the morning or evening dose should be opened and the contents sprinkled onto approximately 100 grams of apple sauce or fruit jam. Gently stir the contents into the soft food, creating a mixture of cysteamine granules and food. The entire amount of the mixture should be eaten. This may be followed by 250 mL of an acceptable acidic liquid - fruit juice (e.g., orange juice or any acidic fruit juice) or water. The mixture must be eaten within 2 hours after preparation and may be refrigerated from the time of preparation to the time of administration.
\*\*\*Administering through feeding tubes\*\*\*
Capsules for either the morning or evening dose should be opened and the contents sprinkled onto approximately 100 grams of apple sauce or fruit jam. Gently stir the contents into the soft food, creating a mixture of cysteamine granules and the soft food. The mixture should then be administered via gastrostomy tube, nasogastric tube or gastrostomy-jejunostomy tube using a catheter tip syringe. Before PROCYSBI administration: Unclasp the G-tube button and attach the feeding tube. Flush with 5 mL of water to clear the button. Draw the mixture up into the syringe. A maximum 60 mL mixture volume in a catheter tip syringe is recommended for use with a straight or bolus feeding tube. Place the opening of the syringe containing the PROCYSBI/apple sauce/fruit jam mixture into the opening of the feeding tube and fill completely with the mixture: pressing gently on the syringe and keeping the feeding tube horizontal during administration can help to avoid clogging issues. Using a viscous food such as apple sauce or fruit jam at a rate of about 10 mL every 10 seconds until the syringe is completely empty, is also suggested to avoid clogging. Repeat the above step until all of the mixture is given. After PROCYSBI administration, draw 10 mL of fruit juice or water up into another syringe and flush the G-tube ensuring that none of the apple sauce/fruit jam and granules mixture gets stuck on the G-tube.
The mixture must be administered within 2 hours after preparation and may be refrigerated from the time of preparation to the time of administration. Nothing of the mixture should be saved.
\*\*\*Sprinkling in orange juice or any acidic fruit juice or water\*\*\*
Capsules for either the morning or evening dose should be opened and the contents sprinkled into 100 to 150 mL of acidic fruit juice or water. Dose administration options are provided below:
• Option 1/Syringe: Mix gently for 5 minutes, then aspirate the mixture of cysteamine granules and acidic fruit juice or water into a dosing syringe.
• Option 2/Cup: Mix gently for 5 minutes in a cup or shake gently for 5 minutes in a covered cup (e.g., “sippy” cup). Drink the mixture of cysteamine granules and acidic fruit juice or water.
The mixture must be administered (drunk) within 30 minutes after preparation and may be refrigerated from the time of preparation to the time of administration.
\*\*Disposal\*\*
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
